Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of patients were able to ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...

Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...